Company* (Symbol)** |
Product | Description |
Indication |
Status (Date)*** |
Agouron Pharmaceuticals Inc. (a subsidiary of Warner-Lambert Co.; NYSE:WLA) |
Prinomastat (formerly AG3340) |
Matrix metalloprotease inhibitor | Advanced non-smallcell lung cancer |
Initiated second Phase III trial in combination with chemotherapy (8/19) |
Aronex Pharmaceuticals Inc. (ARNX) | Atragen | Liposomal formulation of all trans-retinoic acid | Hormone-refractory metastatic prostate cancer | Expanded enrollment in Phase II trial (8/18) |
Celgene Corp. (CELG) and National Cancer Institute | Thalomid |
Thalidomide; thought to act by modulating levels of tumor necrosis factor-alpha | Colorectal cancer | Initiated Phase II trial (8/5) |
Cell Pathways Inc. (CLPA) | CP-461 | Pro-apoptotic, anti-cancer |
Various cancers compound |
Reported completion of Phase Ia trial (8/4) |
ImClone Systems Inc. (IMCL) | C225 |
Monoclonal antibody, an inhibitor of the epidermal growth factor receptor associated with cancer cell growth in a number of solid tumors | Refractory advanced squamous cell head and neck cancer |
Commencemed multi-center Phase II trial in combination with cisplatin (8/11) |
The Liposome Company Inc. (LIPO) | Evacet (formerly TLC D-99) | Proprietary liposomal formulation of doxorubicin | Metastatic or locally advanced breast cancer | Commenced clinical trial in combination with the monoclonal antibody Herceptin (8/4) |
The Liposome Company Inc. (LIPO) and RhonePoulenc Rorer Pharmaceuticals Inc. (NYSE:RP) | Evacet(formerly TLC D-99) |
Proprietary liposomal formulation of doxorubicin | Metastatic breast cancer |
Initiated clinical trial in combination with Taxotere (docetaxel) (8/11) |
The Liposome Company Inc. (LIPO) and Bristol-Myers Squibb Co. (NYSE:BMY) |
Evacet (formerly TLC D-99) | Proprietary liposomal formulation of doxorubicin |
Metastatic breast cancer | Commenced clinical trial collaboration in combination with Taxol (paclitaxel) (8/25) |
Matrix Pharmaceutical Inc. (MATX) |
IntraDose Injectable Gel |
Biodegradable gel combining cisplatin and epinephrine (intratumoral injection) |
Metastatic liver cancer | Completed enrollment in Phase II trial (8/9) |
Maxim Pharmaceuticals (AMEX:MMP; SSE: MAXM) |
Maxamine therapy | H2 receptor agonist; combination therapy with low-dose interleukin-2 | Acute myelogenous leukemia | Reported results of clinical trial (8/31) |
Procept Inc. (NASDAQ SC: PRCT) | 06-Benzylgua-nine |
Chemosensitizing agent that inactivates tumor AGT, a DNA repair protein which interferes with the effectiveness of certain alkylating agents | Breast cancer |
Initiated Phase I trial (8/23) |
06-Benzylgua-nine |
Chemosensitizing agent that inactivates tumor AGT, a DNA repair protein which interferes with the effectiveness of certain alkylating agents |
Cutaneous T-cell lymphoma |
Initiated Phase I trial (8/23) |
|
06-Benzylgua-nine | Chemosensitizing agent that inactivates tumor AGT, a DNA repair protein which interferes with the effectiveness of certain alkylating agents | Treatment of children with primary central nervous system tumors refractory to standard therapy |
Initiated Phase I trial (8/23) |
|
06-Benzylgua-nine |
Chemosensitizing agent that inactivates tumor AGT, a DNA repair protein which interferes with the effectiveness of certain alkylating agents | Patients with a variety of surgically resectable solid tumors |
Initiated Phase I trial (8/23) |
|
Protein Design Labs Inc. (PDLI) |
SMART (humanized) 1D10 antibody | Humanized monoclonal antibody that binds to an HLA-DR determinant found on many pre-B and B-cell lymphomas |
Patients with relapsed non-Hodgkin's lymphoma |
Initiated Phase I trial (8/3) |
Ribozyme Pharmaceuticals Inc. (RZYM) | Angiozyme | Chemically synthesized ribozyme therapeutic; inhibits formation of vascular endothelial growth factor receptor (VEGF-r) | Cancer | Reported results of Phase Ia and Ib trials (8/11) |
Techniclone Corp. (TCLN) |
Cotara (formerly TNT) | Tumor necrosis therapy; chimeric monoclonal antibody that targets DNA-associated histone antigens, labeled with I-131 (targets necrotic center of tumor) |
Malignant glioma |
Expanded Phase II trial (8/11) |
CARDIOVASCULAR | ||||
Centocor Inc. (CNTO) and Eli Lilly and Co. (NYSE:LLY) |
ReoPro (FDA-approved) |
Chimeric monoclonal antibody fragment GPIIb/IIIa platelet receptor (abciximab) |
Heart attack | Reported findings from international clinical trial (8/30) |
CV Therapeutics Inc. (CVTX) | Ranolazine | Perzine acetamide | Stable angina | Reported initial results from Phase III MARISA (monotherapy assessment of Ranolazine in stable angina) trial (8/18) |
Discovery Therapeutics Inc.* |
DTI-0009 |
A selective adenosine A1 agonist |
Paroxysmal supra-ventricular tachycardia; tachcardia associated with atrial fibrillation | Initiated Phase I trial (8/31) |
Emisphere Technologies Inc. (EMIS) | Oral formulation of heparin | Prevention of venous thromboembolic events following elective hip arthroplasty | Reported results of Phase II trial at the XVIIth Congress of the International Society of Thrombosis and Haemostasis (8/19) | |
Interneuron Pharmaceuticals Inc. (IPIC) |
CerAxon |
Citocholine sodium; organic molecule that consists of cytidine and choline (components of brain cell membranes) |
Ischemic stroke | Completed enrollment in Phase III trial (8/26) |
Pharmacyclics Inc. (PCYC) |
Antrin |
Water-soluble photosensitizer that accumulates in atherosclerosis, is cleared rapidly from the blood and is activated by 732 nm |
Photoangioplasty in patients with symptomatic peripheral arterial disease light; drug is intravenously delivered | Reported results from Phase I trial (8/30) |
United Therapeutics Corp. (UTHR) |
UT-15 |
Modified version of prostacyclin molecule | Primary pulmonary hypertension |
Presented results of comparison study at the European Society of Cardiology convention (8/31) |
CENTRAL NERVOUS SYSTEM | ||||
Guilford Pharmaceuticals Inc. (GLFD) and Amgen Inc. (AMGN) |
Class of compounds known as neuroimmunophilins |
Parkinson's disease |
Initiated Phase I trial (8/14) |
|
DIABETES | ||||
Amylin Pharmaceuticals Inc. (AMLN) |
Symlin (pramlintide acetate) | Synthetic analogue of the hormone amylin |
Type 2 diabetes | Reported results of Phase III trial (8/31) |
Generex Biotechnology Corp. (OTC BB: GNBT) |
Bucally administered insulin |
Post-prandial hyper-glycemia |
Reported completion of Phase II trials (8/10) | |
Genzyme Tissue Repair (GZTR) |
TGF-beta2 |
Protein that promotes normal wound healing by stimulating connective tissue growth |
Diabetic foot ulcers |
Reported completion of Phase II trial (8/31) |
Organogenesis Inc. (AMEX:ORG) | Apligraf (FDA-approved) |
Living human skin equivalent, composed of living human keratinocytes and fibroblasts (epidermis and dermis, isolated from infant foreskins) cultured in a 3-dimensional system |
Diabetic foot ulcers | Reported results of pivotal trial (8/25) |
INFECTION | ||||
Avant Immunotherapeutics (AVAN) and Pasteur Merieux Connaught |
Adjumer-formulated vaccine |
Respiratory syncytial virus |
Initiated Phase I trial (8/23) | |
Aviron (AVIR) | Vaccine based on the single surface antigen responsible for most of the neutralizing anti- bodies stimulated by Epstein-Barr virus |
Epstein-Barr virus | Reported results of Phase I trial (8/11) |
|
|
BioCryst Pharmceuticals Inc. (BCRX) and R.W. Johnson Pharmaceutical Research Institute (a unit of Johnson & Johnson; NYSE: JNJ) |
RWJ-270201 |
Neuraminidase inhibitor |
Influenza A |
Reported preliminary Phase II results (8/24) |
Chiron Corp. (CHIR) |
Proleukin (aldesleukin) | Recombinant form of T-cell growth factor (interleukin-2) | HIV patients with low CD4+ T-cell counts |
Commenced patient enrollment in Phase III trial (8/18) |
Nabi (NABI) | StaphVAX |
Capsular polysaccharide conjugate vaccine for Staphylococcus aureus infections |
Treatment of S. aureus infections in hemodialysis patients |
Reported positive interim results from pivotal trial (8/25) |
MISCELLANEOUS | ||||
Alexion Pharmaceuticals Inc. (ALXN) |
5G1.1 |
Anti-inflammatory complement inhibitor | Rheumatoid arthritis |
Initiated Phase II trial (8/4) |
5G1.1 | Anti-inflammatory complement inhibitor |
Membranous nephritis | Initiated Phase II trial (8/11) |
|
Anika Therapeutics Inc. (ANIK) | Orthovisc |
High molecular weight, naturally derived form of hyaluronic acid | Osteoarthritis of the knee |
Completed patient enrollment in Phase III trial (8/19) |
Bayer Corp.* | Kogenate | Recombinant version of a naturally occurring coagulation protein |
Hemophilia A |
Reported results from two clinical trials (8/18) |
BioSpecifics Technologies Corp. (BSTC) |
Plaquase |
Injectable collagenase enzyme |
Peyronie's disease |
Reported positive preliminary results of clinical trial (8/9) |
Bio-Technology General Corp. (BTGC) | BioHy |
High molecular weight sodium | Osteoarthritis of the knee hyaluronate injection | Initiated efficacy study (8/30) |
CytRx Corp. (CYTR) | Flocor |
Purified poloxamer 188; intravenously delivered surfactant molecule that alters the way cells and molecules interact with water |
Acute lung injury | Initiated Phase I/II study (8/30) |
Discovery Laboratories Inc. (NASDAQ SC: DSCO) | SuperVent Aerosol Solution |
Tyloxapol (non-anionic alkylaryl and polyether alcohol) | Cystic fibrosis |
Initiated Phase IIa trial |
Duramed Pharmaceuticals Inc. (DRMD) | Cenestin tablets | Plant-derived (soy and yams) synthetic complex mixture conjugated estrogens product |
Moderate-to-severe vasomotor symptoms associated with menopause |
Completed bioequivalence study (8/4) |
Dynavax Technologies Corp.* | Amb a 1 Immunostimulatory Conjugate (AIC) |
Therapeutic conjugate that induces an enhanced Amb a 1-specific, Th1-type response |
Allergic rhinitis | Reported completion of patient enrollment and dosing in Phase I trial (8/19) |
Eli Lilly & Co. (NYSE:LLY) |
Olanzapine (Zyprexa) |
Selective monoaminergic antagonist belonging to the thienobenzodiazepine class of antipsychotics | Hyperprolactinemia in schizophrenia patients |
Reported results of clinical study (8/2) |
Immunex Corp. (IMNX) |
Enbrel (FDA-approved) |
Etanercept; recombinant, soluble T75 tumor necrosis factor (TNFr) linked to the Fc portion of human IgG1 |
Psoriatic arthritis | Reported clinical trial results (8/16) |
IntraBiotics Pharmaceuticals Inc.* | Protegrin IB-367 |
Synthetic analogue of protegrin family of mammalian antimicrobial peptides (liquid formulation delivered via nebulizer) | Oral mucositis | Reported completion of Phase II trial (8/10) |
Iomed (AMEX:IOX) | IontoDex | Dexamethasone sodium phosphate | Acute local inflammatory conditions |
Initiated Phase III trial (8/11) |
MacroChem Corp. (MCHM) |
Topiglan | 1% alprostadil and 5% | Erectile dysfunction Sepa topical formulation | Reported completion of series of clinical trials (8/4) |
NexMed Inc. (OTC BB:NEXM) |
Femprox |
Proprietary topical formulation combining NexMed's NexACT penetration drug delivery technology with alprostadil |
Female sexual dysfunction |
Reported Phase I trial results (8/6) |
Notes: | ||||
* Indicates a privately held company | ||||
** Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market. | ||||
*** The dates listed indicate the issue dates of press releases. | ||||
